Reprogramming Iron Metabolism via the RIG-I/c-Myc/FTH Axis Mitigates Renal Ischemia-Reperfusion Injury
<b><i>Aims:</i></b> Iron metabolism disorders are critical in the pathogenesis of acute kidney ischemia-reperfusion injury (IRI). However, the molecular mechanisms driving these disturbances remain poorly understood. <b><i>Results:</i></b> In IRI mouse kidneys, pathological alterations, iron metabolism disruptions, and functional impairments were observed. Retinoic acid-inducible gene-I (RIG-I), transcription factor c-Myc, and ferritin heavy chain (FTH) exhibited elevated expression and colocalization in tubular epithelial cells, accompanied by decreased glutathione peroxidase 4 (GPX4) level and evidence of ferroptosis. Further <i>in vitro</i> studies revealed that RIG-I promoted c-Myc activation. The latter demonstrated its positive regulation of FTH transcription by chromatin immunoprecipitation assays and c-Myc siRNA experiments. Interestingly, FTH overexpression resulted in elevated levels of RIG-I, transferrin receptor, ferroportin, and nuclear receptor coactivator 4. Ultimately, the c-Myc inhibitor 10058-F4 reversed all adverse alterations and demonstrated a protective role in IRI mouse kidneys and mouse kidney tubule cells subjected to the ferroptosis inducer erastin, RIG-I agonist, or hypoxia/reoxygenation. This reversal was reflected in improved renal morphology and function, balanced iron metabolism, increased GPX4 level, decreased 4-hydroxynonenal level, reduced inflammatory cell infiltration, interleukin-1 beta release, and kidney injury molecule 1 expression. <b><i>Innovation:</i></b> This study proposes a novel mechanism in which c-Myc is activated by elevated RIG-I in IRI kidneys and positively regulates FTH transcription, therefore involving iron metabolism disorders. <b><i>Conclusions:</i></b> The RIG-I, c-Myc, and FTH disrupt iron homeostasis, and the c-Myc inhibition stabilizes iron metabolism and mitigates oxidative stress, suggesting a potential therapeutic target in IRI. <i>Antioxid. Redox Signal.</i> 43, 622-636. [Figure: see text].
Authors
- Xiao‐Yue Zhai (ORCID: https://orcid.org/0000-0001-5907-8257)
- Linquan Bai (ORCID: https://orcid.org/0000-0002-3269-9747)
- Jia Xing (ORCID: https://orcid.org/0000-0001-7521-9806)
- Hui Peng (ORCID: https://orcid.org/0000-0002-0220-3616)
- Xue Li (ORCID: https://orcid.org/0000-0002-1019-0042)
- Xiling Yi (ORCID: https://orcid.org/0009-0003-2768-4393)
- Hanzhe Liu (ORCID: https://orcid.org/0000-0001-9001-725X)
- Yulu Zhang (ORCID: https://orcid.org/0009-0003-6929-0990)
- Yu Zou (ORCID: https://orcid.org/0000-0001-5699-5869)
- Li Yao (ORCID: https://orcid.org/0000-0002-3979-3832)
- Yang Yu (ORCID: https://orcid.org/0000-0002-0549-8755)
Institutions
- Shenyang First People's Hospital (CN)
- First Hospital of China Medical University (CN)
- Shenyang 242 Hospital (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Jinzhou Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Antioxidants and Redox Signaling
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1177/15230864251369883
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00